Liquidia Stock Slides After Court Rules YUTREPIA Infringed on United Therapeutics Patent

Shares of Liquidia Corporation (NASDAQ: LQDA) extended their decline Tuesday, falling 5.2% in pre-market trading to $28.70 as investors continued to react to an adverse patent infringement ruling. The decision, handed down by a federal court, found that Liquidia's flagship therapy for pulmonary hypertension infringed on a patent held by competitor United Therapeutics.

The Court's Decision

The U.S. District Court for the District of Delaware ruled that Liquidia’s inhaled therapy, YUTREPIA, infringed on claims 1 and 14 of U.S. Patent No. 11,826,327, held by United Therapeutics. The patent specifically covers the use of inhaled treprostinil for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The commercial impact of the verdict is significant, as the PH-ILD indication represents approximately half of YUTREPIA's total addressable market. In response, Liquidia announced it will submit a supplement to the FDA to remove the PH-ILD indication from YUTREPIA's label. The situation could be further complicated as United Therapeutics has requested injunctive relief that may seek to restrict the drug's broader market availability.

Market and Analyst Reaction

Ad

The fallout from the ruling was swift. In addition to the stock's decline, several factors are weighing on investor sentiment:

• Analyst Downgrade: BTIG downgraded Liquidia's stock from Buy to Neutral following the court's decision.
• Competitor Gains: In a direct reflection of the zero-sum nature of the patent dispute, shares of United Therapeutics (NASDAQ: UTHR) surged on the news.
• Future Uncertainty: Both parties have been directed to submit proposed remedies to the court within one week, leaving the final scope of commercial restrictions on YUTREPIA uncertain. Analysts at RBC Capital noted the ruling creates "significant obstacles" for the drug's competitive future.

While Liquidia CEO Roger Jeffs stated the company "respectfully disagree[s] with the Court’s decision" and is "fully prepared to pursue all available appellate options," he also acknowledged that the company's financial exposure cannot yet be quantified. The stock is now trading substantially below its 52-week high of $93.61 as the market awaits the court's final determination on remedies.